TFX Teleflex Incorporated

Teleflex Incorporated Signs New Agreement with Premier Inc. for Implantable Infusion Ports

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced a new group purchasing agreement with Premier Inc. – a leading healthcare improvement company, uniting an alliance of approximately 3,750 US hospitals and 130,000 other providers to transform healthcare. The new agreement covers the Polysite® Low Profile Hybrid Ports. The agreement begins November 1, 2016, and extends through October 31, 2019.

The Polysite® Low Profile Hybrid Ports are designed to enhance patient comfort while simultaneously providing clinicians with unique product enhancements. The low-profile design incorporates hybrid technology with a durable titanium reservoir and a lightweight atraumatic-angled shell. The ports have a large septum for easy access and include a radiopaque locking collar for safe attachment to catheters. They are available in both pressure-injectable and non-pressure-injectable options in 6Fr, 7Fr and 8Fr sizes.

“Arrow® Interventional Access products from Teleflex provide economical solutions and help clinicians to reduce complications,” said Jay White, President and General Manager, Vascular Division of Teleflex. “We’re pleased to offer Premier members the clinical and financial benefits of the Polysite Ports under this new agreement.”

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose-driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.

Polysite is a registered trademark of Perouse Medical SAS.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2016 Teleflex Incorporated. All rights reserved. MC-002818

EN
28/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

Teleflex Inc: 5 directors

Five Directors at Teleflex Inc bought 5,500 shares at between 114.750USD and 115.860USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

 PRESS RELEASE

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthc...

 PRESS RELEASE

Teleflex Reports Second Quarter Financial Results and Full Year 2025 O...

Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis  GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the prior year...

 PRESS RELEASE

Teleflex Announces Second Quarter 2025 Earnings Conference Call Inform...

Teleflex Announces Second Quarter 2025 Earnings Conference Call Information WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, . An audio replay of the call will be available beginning at 11:00 am Easter...

 PRESS RELEASE

Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Bu...

Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch